Sign Up
Stories
Biopharmaceutical Companies Merge and Present at Conferences
Share
4DMT Presents Positive Interim Data
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Overview
API
LENZ Therapeutics and Graphite Bio have announced a merger agreement to create a biopharmaceutical company focused on advancing LENZ Therapeutics lead assets for the treatment of presbyopia. Opthea, a biopharmaceutical company, will present at the Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference. Opthea has appointed Frederic Guerard as CEO and Peter Lang as CFO. The company will also participate in the 2023 Euretina Congress and feature its lead product candidate, OPT-302, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting.
Ask a question
How might the appointment of new leadership at Opthea influence the company's growth and development?
How might the merger agreement between LENZ Therapeutics and Graphite Bio impact the development of treatments for presbyopia?
What are the potential implications of Opthea's lead product candidate, OPT-302, on the treatment of wet AMD and diabetic macular edema?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Oct 2023
Coverage
Oct